文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-PSMA-617 治疗转移性去势抵抗性前列腺癌 50 例扩展 II 期试验的长期随访与再治疗结局

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · J Nucl Med · 2019-11-15

这项单中心 II 期前瞻性扩展队列纳入 50 例经多线治疗后进展的 PSMA 阳性转移性去势抵抗性前列腺癌患者,接受最多 4 周期 177Lu-PSMA-617 治疗。结果显示 64% 患者 PSA 下降≥50%,客观缓解率 56%,毒性以 G1-G2 口干和恶心为主;中位随访 31.4 个月时中位总生存 13.3 个月,PSA 应答者生存更长。进展后再次 177Lu-PSMA 治疗的 PSA 应答率高于其他系统治疗。

要点

  • 50 例经多线治疗患者中 64% 达 PSA 下降≥50%,44% 达≥80%。
  • 可测量软组织病灶患者 RECIST 1.1 客观缓解率为 56%。
  • 进展后再次 177Lu-PSMA 治疗 73% 达 PSA 下降≥50%,高于其他系统治疗的 19%。

核心结论

  • 在经广泛治疗的转移性去势抵抗性前列腺癌患者中,177Lu-PSMA-617 放射配体治疗具有高应答率、低毒性和改善生活质量的效果。
  • 疾病进展后再次使用 177Lu-PSMA-617 的 PSA 应答率高于其他系统治疗。

研究设计与样本

  • 单中心 II 期前瞻性扩展队列研究,共纳入 50 例 PSMA 阳性的转移性去势抵抗性前列腺癌患者。
  • 患者接受最多 4 周期 177Lu-PSMA-617 治疗,每 6 周一次,平均给药放射性活度为 7.5 GBq/周期。

主要发现

  • 32/50(64%;95%CI 50%-77%)患者 PSA 下降≥50%,其中 22 例(44%;95%CI 30%-59%)下降≥80%。
  • 27 例可测量软组织病灶患者中 15 例(56%)达 RECIST 1.1 客观缓解。
  • 中位随访 31.4 个月时中位总生存为 13.3 个月(95%CI 10.5-18.7 个月),PSA 下降≥50% 者中位总生存为 18.4 个月(95%CI 13.8-23.8 个月)。
  • 常见毒性为自限性 G1-G2 口干(66%)、一过性 G1-G2 恶心(48%)、G3-G4 血小板减少(10%)和 G3 贫血(10%)。
  • Brief Pain Inventory 严重程度和干扰评分在所有时间点均下降,3 个月随访时分别下降 -1.2(95%CI -0.5 至 -1.9;P=0.001)和 -1.0(95%CI -0.2 至 -0.18;P=0.013)。

关键数值与推荐

  • PSA 应答按 Prostate Cancer Working Group 2 标准评估。
  • 毒性按 Common Terminology Criteria for Adverse Events 4.03 版分级。
  • 影像学应答按 RECIST 1.1 标准评估。

临床怎么用

  • 对于经多线治疗(包括多西他赛、卡巴他赛、阿比特龙或恩扎卢胺)后进展的 PSMA 阳性转移性去势抵抗性前列腺癌患者,177Lu-PSMA-617 可作为治疗选择。
  • 治疗过程中需监测血液学毒性,尤其是血小板减少和贫血。
  • 疾病进展后再次 177Lu-PSMA-617 治疗可能优于其他系统治疗,但需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

177Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen (PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported favorable activity with low toxicity in a prospective phase II trial involving 30 men with metastatic castration-resistant prostate cancer. We now report their longer-term outcomes, including a 20-patient extension cohort and outcomes of subsequent systemic treatments after completion of trial therapy. Methods: Fifty patients with PSMA-avid metastatic castration-resistant prostate cancer who had progressed after standard therapies received up to 4 cycles of 177Lu-PSMA every 6 wk. Endpoints included prostate-specific antigen (PSA) response (Prostate Cancer Working Group 2), toxicity (Common Terminology Criteria for Adverse Events, version 4.03), imaging response, patient-reported health-related quality of life, progression-free survival, and overall survival. We also describe, as a novel finding, outcomes of men who subsequently progressed and had further systemic therapies, including 177Lu-PSMA. Results: Seventy-five men were screened to identify 50 patients eligible for treatment. Adverse prognostic features of the cohort included short median PSA doubling time (2.3 mo) and extensive prior treatment, including prior docetaxel (84%), cabazitaxel (48%), and abiraterone or enzalutamide (92%). The mean administered radioactivity was 7.5 GBq/cycle. A PSA decline of at least 50% was achieved in 32 of 50 patients (64%; 95% confidence interval [CI], 50%-77%), including 22 patients (44%; 95% CI, 30%-59%) with at least an 80% decrease. Of 27 patients with measurable soft-tissue disease, 15 (56%) achieved an objective response by RECIST 1.1. The most common toxicities attributed to 177Lu-PSMA were self-limiting G1-G2 dry mouth (66%), transient G1-G2 nausea (48%), G3-G4 thrombocytopenia (10%), and G3 anemia (10%). Brief Pain Inventory severity and interference scores decreased at all time points, including at the 3-mo follow-up, with a decrease of -1.2 (95% CI, -0.5 to -1.9; P = 0.001) and -1.0 (95% CI, -0.2 to -0.18; P = 0.013), respectively. At a median follow-up of 31.4 mo, median overall survival was 13.3 mo (95% CI, 10.5-18.7 mo), with a significantly longer survival of 18.4 mo (95% CI, 13.8-23.8 mo) in patients achieving a PSA decline of at least 50%. At progression after prior response, further 177Lu-PSMA was administered to 15 (30%) patients (median of 2 cycles commencing 359 d from enrollment), with a PSA decline of at least 50% in 11 patients (73%). Four of 21 patients (19%) receiving other systemic therapies on progression experienced a PSA decline of at least 50%. There were no unexpected adverse events with 177Lu-PSMA retreatment. Conclusion: This expanded 50-patient cohort of men with extensive prior therapy confirms our earlier report of high response rates, low toxicity, and improved quality of life with 177Lu-PSMA radioligand therapy. On progression, rechallenge 177Lu-PSMA demonstrated higher response rates than other systemic therapies.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Violet J, Sandhu S, Iravani A, et al. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2019. PMID: 31732676. doi:10.2967/jnumed.119.236414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。